ZyGEM and VWR International Sign Agreement to Distribute DNA Extraction Technology
News Nov 18, 2008
ZyGEM Corp. Ltd. and VWR International, LLC have announced that they have entered into an exclusive distribution agreement for ZyGEM’s DNA extraction kits.
Under the terms of the agreement, VWR will have exclusive rights to distribute ZyGEM’s DNA extraction products to the life science research, forensic, diagnostic, agriculture and animal health markets in North America and South America.
VWR will distribute the highly diversified product line to the pharmaceutical and biotech companies, as well as industrial, educational and governmental organizations.
“Our DNA extraction technology represents a breakthrough in simplicity, cost-effectiveness, speed and accuracy, and we are delighted at this agreement with VWR to make these versatile kits readily available to scientists in the Americas,” said Paul Kinnon, CEO of ZyGEM.
“We believe this technology is transforming and expect that greater access to our DNA extraction kits will facilitate the growing use of genetic analyses in diverse applications. This is the most significant in a series of recent ZyGEM agreements intended to increase access to our cutting-edge products, and we look forward to working with VWR to support the wide availability of these innovative products,” Kinnon added.
ZyGEM’s technology uses a proprietary thermophilic enzyme to extract DNA from samples using a single closed-tube system. ZyGEM’s approach can reduce the time and cost of DNA extractions while simplifying laboratory workflow, minimizing error, reducing the risk of contamination, ensuring sample integrity and facilitating extractions from trace samples.
The technology is easily adaptable for use with virtually all off-the-shelf laboratory automation systems. The technology can be specifically formulated for use with a wide range of different sample types without the need for further purification. ZyGEM’s technology has been validated for use in highly regulated applications including forensic analysis.
Further terms of the agreement were not disclosed.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.